Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bee venom phospholipase A2
- Development stage
- Unknown
- Modality
- Therapeutic Enzymes → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous, Intraperitoneal, Intratracheal, Topical
01
Overview
Bee venom phospholipase A2 (bvPLA2) is a major enzymatic component of honeybee (*Apis mellifera*) venom that functions as both a lipolytic enzyme and a potent immunomodulator. It primarily exerts its therapeutic effects by binding to the CD206 mannose receptor on dendritic cells, which triggers the expansion of CD4+ CD25+ Foxp3+ regulatory T cells (Tregs) via the PGE2-EP2 signaling pathway. Additionally, bvPLA2 has been shown to inhibit the STAT3 signaling pathway, reduce neuroinflammation, and modulate microglial activation. A standardized, fortified formulation known as New Composition Bee Venom (NCBV) is currently in Phase 1 development for the treatment of Alzheimer's disease, while the purified enzyme is being investigated for Parkinson's disease, rheumatoid arthritis, atopic dermatitis, and various inflammatory disorders.
- Other names
- bvPLA2bvPLA-2bvPLA 2honey bee venom phospholipase A2Apis mellifera phospholipase A2
02
Targets
STAT3 (Signal Transducer and Activator of Transcription 3)MRC1 (Mannose Receptor C-type 1)
Beyond the preview
Go deeper on bee venom phospholipase A2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bee venom phospholipase A2.